カテゴリー： Market Monitor Global, 世界, 医療/バイオ

ウイルス様粒子の世界市場見通し2023年-2029年

◆英語タイトル：Virus Like Particles Market, Global Outlook and Forecast 2023-2029
	◆商品コード：MMG23LY8750 ◆発行会社（リサーチ会社）：Market Monitor Global ◆発行日：2023年7月（※2025年版があります。お問い合わせください。） ◆ページ数：116 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後2-3営業日） ◆調査対象地域：グローバル ◆産業分野：医薬品＆ヘルスケア

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥468,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥608,400	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥702,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global Virus Like Particles Market 調査レポートは次の情報を含め、グローバルにおけるのウイルス様粒子市場規模と予測を収録しています。・世界のウイルス様粒子市場：売上、2018年-2023年、2024年-2029年
・世界のウイルス様粒子市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界のウイルス様粒子市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「アデノ随伴ウイルス」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

ウイルス様粒子のグローバル主要企業は、GlaxoSmithKline、 Merck、 Novavax、 Takeda、 Medicago、 MedImmune、 TechnoVax、 Agilvax、 Allergy Therapeutics、 Serum Institute of India、 GeoVax Labs、 Cytos Biotechnology、 ANGANY Genetics、 CPL Biologicals、 Xiamen Innovax Biotechなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、ウイルス様粒子のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界のウイルス様粒子市場：タイプ別、2018年-2023年、2024年-2029年
世界のウイルス様粒子市場：タイプ別市場シェア、2022年
・アデノ随伴ウイルス、HIV、B型肝炎ウイルス、C型肝炎ウイルス、その他

世界のウイルス様粒子市場：用途別、2018年-2023年、2024年-2029年
世界のウイルス様粒子市場：用途別市場シェア、2022年
・ワクチン、マイコウイルス、ウイルス研究、治療薬・画像診断薬、その他

世界のウイルス様粒子市場：地域・国別、2018年-2023年、2024年-2029年
世界のウイルス様粒子市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業におけるウイルス様粒子のグローバル売上、2018年-2023年
・主要企業におけるウイルス様粒子のグローバル売上シェア、2022年
・主要企業におけるウイルス様粒子のグローバル販売量、2018年-2023年
・主要企業におけるウイルス様粒子のグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
GlaxoSmithKline、 Merck、 Novavax、 Takeda、 Medicago、 MedImmune、 TechnoVax、 Agilvax、 Allergy Therapeutics、 Serum Institute of India、 GeoVax Labs、 Cytos Biotechnology、 ANGANY Genetics、 CPL Biologicals、 Xiamen Innovax Biotech

*************************************************************

・調査・分析レポートの概要
ウイルス様粒子市場の定義
市場セグメント
世界のウイルス様粒子市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界のウイルス様粒子市場規模
世界のウイルス様粒子市場規模：2022年 VS 2029年
世界のウイルス様粒子市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでのウイルス様粒子の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業のウイルス様粒子製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：アデノ随伴ウイルス、HIV、B型肝炎ウイルス、C型肝炎ウイルス、その他
ウイルス様粒子のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：ワクチン、マイコウイルス、ウイルス研究、治療薬・画像診断薬、その他
ウイルス様粒子の用途別グローバル売上・予測

・地域別市場分析
地域別ウイルス様粒子市場規模 2022年と2029年
地域別ウイルス様粒子売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
GlaxoSmithKline、 Merck、 Novavax、 Takeda、 Medicago、 MedImmune、 TechnoVax、 Agilvax、 Allergy Therapeutics、 Serum Institute of India、 GeoVax Labs、 Cytos Biotechnology、 ANGANY Genetics、 CPL Biologicals、 Xiamen Innovax Biotech
...

This report aims to provide a comprehensive presentation of the global market for Virus Like Particles, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Virus Like Particles. This report contains market size and forecasts of Virus Like Particles in global, including the following market information:
Global Virus Like Particles Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Virus Like Particles Market Sales, 2018-2023, 2024-2029, (K Dose)
Global top five Virus Like Particles companies in 2022 (%)
The global Virus Like Particles market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Adeno-Associated Virus Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Virus Like Particles include GlaxoSmithKline, Merck, Novavax, Takeda, Medicago, MedImmune, TechnoVax, Agilvax and Allergy Therapeutics, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Virus Like Particles manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Virus Like Particles Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Dose)
Global Virus Like Particles Market Segment Percentages, by Type, 2022 (%)
Adeno-Associated Virus
HIV
Hepatitis B Virus
Hepatitis C Virus
Others
Global Virus Like Particles Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Dose)
Global Virus Like Particles Market Segment Percentages, by Application, 2022 (%)
Vaccines
Mycoviruses
Virus Research
Therapeutic and Imaging Agents
Others
Global Virus Like Particles Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Dose)
Global Virus Like Particles Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Virus Like Particles revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Virus Like Particles revenues share in global market, 2022 (%)
Key companies Virus Like Particles sales in global market, 2018-2023 (Estimated), (K Dose)
Key companies Virus Like Particles sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
GlaxoSmithKline
Merck
Novavax
Takeda
Medicago
MedImmune
TechnoVax
Agilvax
Allergy Therapeutics
Serum Institute of India
GeoVax Labs
Cytos Biotechnology
ANGANY Genetics
CPL Biologicals
Xiamen Innovax Biotech
Outline of Major Chapters:
Chapter 1: Introduces the definition of Virus Like Particles, market overview.
Chapter 2: Global Virus Like Particles market size in revenue and volume.
Chapter 3: Detailed analysis of Virus Like Particles manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Virus Like Particles in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Virus Like Particles capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Virus Like Particles Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Virus Like Particles Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Virus Like Particles Overall Market Size
2.1 Global Virus Like Particles Market Size: 2022 VS 2029
2.2 Global Virus Like Particles Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Virus Like Particles Sales: 2018-2029
3 Company Landscape
3.1 Top Virus Like Particles Players in Global Market
3.2 Top Global Virus Like Particles Companies Ranked by Revenue
3.3 Global Virus Like Particles Revenue by Companies
3.4 Global Virus Like Particles Sales by Companies
3.5 Global Virus Like Particles Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Virus Like Particles Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Virus Like Particles Product Type
3.8 Tier 1, Tier 2 and Tier 3 Virus Like Particles Players in Global Market
3.8.1 List of Global Tier 1 Virus Like Particles Companies
3.8.2 List of Global Tier 2 and Tier 3 Virus Like Particles Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Virus Like Particles Market Size Markets, 2022 & 2029
4.1.2 Adeno-Associated Virus
4.1.3 HIV
4.1.4 Hepatitis B Virus
4.1.5 Hepatitis C Virus
4.1.6 Others
4.2 By Type – Global Virus Like Particles Revenue & Forecasts
4.2.1 By Type – Global Virus Like Particles Revenue, 2018-2023
4.2.2 By Type – Global Virus Like Particles Revenue, 2024-2029
4.2.3 By Type – Global Virus Like Particles Revenue Market Share, 2018-2029
4.3 By Type – Global Virus Like Particles Sales & Forecasts
4.3.1 By Type – Global Virus Like Particles Sales, 2018-2023
4.3.2 By Type – Global Virus Like Particles Sales, 2024-2029
4.3.3 By Type – Global Virus Like Particles Sales Market Share, 2018-2029
4.4 By Type – Global Virus Like Particles Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Virus Like Particles Market Size, 2022 & 2029
5.1.2 Vaccines
5.1.3 Mycoviruses
5.1.4 Virus Research
5.1.5 Therapeutic and Imaging Agents
5.1.6 Others
5.2 By Application – Global Virus Like Particles Revenue & Forecasts
5.2.1 By Application – Global Virus Like Particles Revenue, 2018-2023
5.2.2 By Application – Global Virus Like Particles Revenue, 2024-2029
5.2.3 By Application – Global Virus Like Particles Revenue Market Share, 2018-2029
5.3 By Application – Global Virus Like Particles Sales & Forecasts
5.3.1 By Application – Global Virus Like Particles Sales, 2018-2023
5.3.2 By Application – Global Virus Like Particles Sales, 2024-2029
5.3.3 By Application – Global Virus Like Particles Sales Market Share, 2018-2029
5.4 By Application – Global Virus Like Particles Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Virus Like Particles Market Size, 2022 & 2029
6.2 By Region – Global Virus Like Particles Revenue & Forecasts
6.2.1 By Region – Global Virus Like Particles Revenue, 2018-2023
6.2.2 By Region – Global Virus Like Particles Revenue, 2024-2029
6.2.3 By Region – Global Virus Like Particles Revenue Market Share, 2018-2029
6.3 By Region – Global Virus Like Particles Sales & Forecasts
6.3.1 By Region – Global Virus Like Particles Sales, 2018-2023
6.3.2 By Region – Global Virus Like Particles Sales, 2024-2029
6.3.3 By Region – Global Virus Like Particles Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Virus Like Particles Revenue, 2018-2029
6.4.2 By Country – North America Virus Like Particles Sales, 2018-2029
6.4.3 US Virus Like Particles Market Size, 2018-2029
6.4.4 Canada Virus Like Particles Market Size, 2018-2029
6.4.5 Mexico Virus Like Particles Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Virus Like Particles Revenue, 2018-2029
6.5.2 By Country – Europe Virus Like Particles Sales, 2018-2029
6.5.3 Germany Virus Like Particles Market Size, 2018-2029
6.5.4 France Virus Like Particles Market Size, 2018-2029
6.5.5 U.K. Virus Like Particles Market Size, 2018-2029
6.5.6 Italy Virus Like Particles Market Size, 2018-2029
6.5.7 Russia Virus Like Particles Market Size, 2018-2029
6.5.8 Nordic Countries Virus Like Particles Market Size, 2018-2029
6.5.9 Benelux Virus Like Particles Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Virus Like Particles Revenue, 2018-2029
6.6.2 By Region – Asia Virus Like Particles Sales, 2018-2029
6.6.3 China Virus Like Particles Market Size, 2018-2029
6.6.4 Japan Virus Like Particles Market Size, 2018-2029
6.6.5 South Korea Virus Like Particles Market Size, 2018-2029
6.6.6 Southeast Asia Virus Like Particles Market Size, 2018-2029
6.6.7 India Virus Like Particles Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Virus Like Particles Revenue, 2018-2029
6.7.2 By Country – South America Virus Like Particles Sales, 2018-2029
6.7.3 Brazil Virus Like Particles Market Size, 2018-2029
6.7.4 Argentina Virus Like Particles Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Virus Like Particles Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Virus Like Particles Sales, 2018-2029
6.8.3 Turkey Virus Like Particles Market Size, 2018-2029
6.8.4 Israel Virus Like Particles Market Size, 2018-2029
6.8.5 Saudi Arabia Virus Like Particles Market Size, 2018-2029
6.8.6 UAE Virus Like Particles Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 GlaxoSmithKline
7.1.1 GlaxoSmithKline Company Summary
7.1.2 GlaxoSmithKline Business Overview
7.1.3 GlaxoSmithKline Virus Like Particles Major Product Offerings
7.1.4 GlaxoSmithKline Virus Like Particles Sales and Revenue in Global (2018-2023)
7.1.5 GlaxoSmithKline Key News & Latest Developments
7.2 Merck
7.2.1 Merck Company Summary
7.2.2 Merck Business Overview
7.2.3 Merck Virus Like Particles Major Product Offerings
7.2.4 Merck Virus Like Particles Sales and Revenue in Global (2018-2023)
7.2.5 Merck Key News & Latest Developments
7.3 Novavax
7.3.1 Novavax Company Summary
7.3.2 Novavax Business Overview
7.3.3 Novavax Virus Like Particles Major Product Offerings
7.3.4 Novavax Virus Like Particles Sales and Revenue in Global (2018-2023)
7.3.5 Novavax Key News & Latest Developments
7.4 Takeda
7.4.1 Takeda Company Summary
7.4.2 Takeda Business Overview
7.4.3 Takeda Virus Like Particles Major Product Offerings
7.4.4 Takeda Virus Like Particles Sales and Revenue in Global (2018-2023)
7.4.5 Takeda Key News & Latest Developments
7.5 Medicago
7.5.1 Medicago Company Summary
7.5.2 Medicago Business Overview
7.5.3 Medicago Virus Like Particles Major Product Offerings
7.5.4 Medicago Virus Like Particles Sales and Revenue in Global (2018-2023)
7.5.5 Medicago Key News & Latest Developments
7.6 MedImmune
7.6.1 MedImmune Company Summary
7.6.2 MedImmune Business Overview
7.6.3 MedImmune Virus Like Particles Major Product Offerings
7.6.4 MedImmune Virus Like Particles Sales and Revenue in Global (2018-2023)
7.6.5 MedImmune Key News & Latest Developments
7.7 TechnoVax
7.7.1 TechnoVax Company Summary
7.7.2 TechnoVax Business Overview
7.7.3 TechnoVax Virus Like Particles Major Product Offerings
7.7.4 TechnoVax Virus Like Particles Sales and Revenue in Global (2018-2023)
7.7.5 TechnoVax Key News & Latest Developments
7.8 Agilvax
7.8.1 Agilvax Company Summary
7.8.2 Agilvax Business Overview
7.8.3 Agilvax Virus Like Particles Major Product Offerings
7.8.4 Agilvax Virus Like Particles Sales and Revenue in Global (2018-2023)
7.8.5 Agilvax Key News & Latest Developments
7.9 Allergy Therapeutics
7.9.1 Allergy Therapeutics Company Summary
7.9.2 Allergy Therapeutics Business Overview
7.9.3 Allergy Therapeutics Virus Like Particles Major Product Offerings
7.9.4 Allergy Therapeutics Virus Like Particles Sales and Revenue in Global (2018-2023)
7.9.5 Allergy Therapeutics Key News & Latest Developments
7.10 Serum Institute of India
7.10.1 Serum Institute of India Company Summary
7.10.2 Serum Institute of India Business Overview
7.10.3 Serum Institute of India Virus Like Particles Major Product Offerings
7.10.4 Serum Institute of India Virus Like Particles Sales and Revenue in Global (2018-2023)
7.10.5 Serum Institute of India Key News & Latest Developments
7.11 GeoVax Labs
7.11.1 GeoVax Labs Company Summary
7.11.2 GeoVax Labs Virus Like Particles Business Overview
7.11.3 GeoVax Labs Virus Like Particles Major Product Offerings
7.11.4 GeoVax Labs Virus Like Particles Sales and Revenue in Global (2018-2023)
7.11.5 GeoVax Labs Key News & Latest Developments
7.12 Cytos Biotechnology
7.12.1 Cytos Biotechnology Company Summary
7.12.2 Cytos Biotechnology Virus Like Particles Business Overview
7.12.3 Cytos Biotechnology Virus Like Particles Major Product Offerings
7.12.4 Cytos Biotechnology Virus Like Particles Sales and Revenue in Global (2018-2023)
7.12.5 Cytos Biotechnology Key News & Latest Developments
7.13 ANGANY Genetics
7.13.1 ANGANY Genetics Company Summary
7.13.2 ANGANY Genetics Virus Like Particles Business Overview
7.13.3 ANGANY Genetics Virus Like Particles Major Product Offerings
7.13.4 ANGANY Genetics Virus Like Particles Sales and Revenue in Global (2018-2023)
7.13.5 ANGANY Genetics Key News & Latest Developments
7.14 CPL Biologicals
7.14.1 CPL Biologicals Company Summary
7.14.2 CPL Biologicals Business Overview
7.14.3 CPL Biologicals Virus Like Particles Major Product Offerings
7.14.4 CPL Biologicals Virus Like Particles Sales and Revenue in Global (2018-2023)
7.14.5 CPL Biologicals Key News & Latest Developments
7.15 Xiamen Innovax Biotech
7.15.1 Xiamen Innovax Biotech Company Summary
7.15.2 Xiamen Innovax Biotech Business Overview
7.15.3 Xiamen Innovax Biotech Virus Like Particles Major Product Offerings
7.15.4 Xiamen Innovax Biotech Virus Like Particles Sales and Revenue in Global (2018-2023)
7.15.5 Xiamen Innovax Biotech Key News & Latest Developments
8 Global Virus Like Particles Production Capacity, Analysis
8.1 Global Virus Like Particles Production Capacity, 2018-2029
8.2 Virus Like Particles Production Capacity of Key Manufacturers in Global Market
8.3 Global Virus Like Particles Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Virus Like Particles Supply Chain Analysis
10.1 Virus Like Particles Industry Value Chain
10.2 Virus Like Particles Upstream Market
10.3 Virus Like Particles Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Virus Like Particles Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Virus Like Particles in Global Market
Table 2. Top Virus Like Particles Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Virus Like Particles Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Virus Like Particles Revenue Share by Companies, 2018-2023
Table 5. Global Virus Like Particles Sales by Companies, (K Dose), 2018-2023
Table 6. Global Virus Like Particles Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Virus Like Particles Price (2018-2023) & (USD/Dose)
Table 8. Global Manufacturers Virus Like Particles Product Type
Table 9. List of Global Tier 1 Virus Like Particles Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Virus Like Particles Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Virus Like Particles Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Virus Like Particles Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Virus Like Particles Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Virus Like Particles Sales (K Dose), 2018-2023
Table 15. By Type - Global Virus Like Particles Sales (K Dose), 2024-2029
Table 16. By Application – Global Virus Like Particles Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Virus Like Particles Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Virus Like Particles Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Virus Like Particles Sales (K Dose), 2018-2023
Table 20. By Application - Global Virus Like Particles Sales (K Dose), 2024-2029
Table 21. By Region – Global Virus Like Particles Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Virus Like Particles Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Virus Like Particles Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Virus Like Particles Sales (K Dose), 2018-2023
Table 25. By Region - Global Virus Like Particles Sales (K Dose), 2024-2029
Table 26. By Country - North America Virus Like Particles Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Virus Like Particles Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Virus Like Particles Sales, (K Dose), 2018-2023
Table 29. By Country - North America Virus Like Particles Sales, (K Dose), 2024-2029
Table 30. By Country - Europe Virus Like Particles Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Virus Like Particles Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Virus Like Particles Sales, (K Dose), 2018-2023
Table 33. By Country - Europe Virus Like Particles Sales, (K Dose), 2024-2029
Table 34. By Region - Asia Virus Like Particles Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Virus Like Particles Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Virus Like Particles Sales, (K Dose), 2018-2023
Table 37. By Region - Asia Virus Like Particles Sales, (K Dose), 2024-2029
Table 38. By Country - South America Virus Like Particles Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Virus Like Particles Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Virus Like Particles Sales, (K Dose), 2018-2023
Table 41. By Country - South America Virus Like Particles Sales, (K Dose), 2024-2029
Table 42. By Country - Middle East & Africa Virus Like Particles Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Virus Like Particles Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Virus Like Particles Sales, (K Dose), 2018-2023
Table 45. By Country - Middle East & Africa Virus Like Particles Sales, (K Dose), 2024-2029
Table 46. GlaxoSmithKline Company Summary
Table 47. GlaxoSmithKline Virus Like Particles Product Offerings
Table 48. GlaxoSmithKline Virus Like Particles Sales (K Dose), Revenue (US$, Mn) and Average Price (USD/Dose) (2018-2023)
Table 49. GlaxoSmithKline Key News & Latest Developments
Table 50. Merck Company Summary
Table 51. Merck Virus Like Particles Product Offerings
Table 52. Merck Virus Like Particles Sales (K Dose), Revenue (US$, Mn) and Average Price (USD/Dose) (2018-2023)
Table 53. Merck Key News & Latest Developments
Table 54. Novavax Company Summary
Table 55. Novavax Virus Like Particles Product Offerings
Table 56. Novavax Virus Like Particles Sales (K Dose), Revenue (US$, Mn) and Average Price (USD/Dose) (2018-2023)
Table 57. Novavax Key News & Latest Developments
Table 58. Takeda Company Summary
Table 59. Takeda Virus Like Particles Product Offerings
Table 60. Takeda Virus Like Particles Sales (K Dose), Revenue (US$, Mn) and Average Price (USD/Dose) (2018-2023)
Table 61. Takeda Key News & Latest Developments
Table 62. Medicago Company Summary
Table 63. Medicago Virus Like Particles Product Offerings
Table 64. Medicago Virus Like Particles Sales (K Dose), Revenue (US$, Mn) and Average Price (USD/Dose) (2018-2023)
Table 65. Medicago Key News & Latest Developments
Table 66. MedImmune Company Summary
Table 67. MedImmune Virus Like Particles Product Offerings
Table 68. MedImmune Virus Like Particles Sales (K Dose), Revenue (US$, Mn) and Average Price (USD/Dose) (2018-2023)
Table 69. MedImmune Key News & Latest Developments
Table 70. TechnoVax Company Summary
Table 71. TechnoVax Virus Like Particles Product Offerings
Table 72. TechnoVax Virus Like Particles Sales (K Dose), Revenue (US$, Mn) and Average Price (USD/Dose) (2018-2023)
Table 73. TechnoVax Key News & Latest Developments
Table 74. Agilvax Company Summary
Table 75. Agilvax Virus Like Particles Product Offerings
Table 76. Agilvax Virus Like Particles Sales (K Dose), Revenue (US$, Mn) and Average Price (USD/Dose) (2018-2023)
Table 77. Agilvax Key News & Latest Developments
Table 78. Allergy Therapeutics Company Summary
Table 79. Allergy Therapeutics Virus Like Particles Product Offerings
Table 80. Allergy Therapeutics Virus Like Particles Sales (K Dose), Revenue (US$, Mn) and Average Price (USD/Dose) (2018-2023)
Table 81. Allergy Therapeutics Key News & Latest Developments
Table 82. Serum Institute of India Company Summary
Table 83. Serum Institute of India Virus Like Particles Product Offerings
Table 84. Serum Institute of India Virus Like Particles Sales (K Dose), Revenue (US$, Mn) and Average Price (USD/Dose) (2018-2023)
Table 85. Serum Institute of India Key News & Latest Developments
Table 86. GeoVax Labs Company Summary
Table 87. GeoVax Labs Virus Like Particles Product Offerings
Table 88. GeoVax Labs Virus Like Particles Sales (K Dose), Revenue (US$, Mn) and Average Price (USD/Dose) (2018-2023)
Table 89. GeoVax Labs Key News & Latest Developments
Table 90. Cytos Biotechnology Company Summary
Table 91. Cytos Biotechnology Virus Like Particles Product Offerings
Table 92. Cytos Biotechnology Virus Like Particles Sales (K Dose), Revenue (US$, Mn) and Average Price (USD/Dose) (2018-2023)
Table 93. Cytos Biotechnology Key News & Latest Developments
Table 94. ANGANY Genetics Company Summary
Table 95. ANGANY Genetics Virus Like Particles Product Offerings
Table 96. ANGANY Genetics Virus Like Particles Sales (K Dose), Revenue (US$, Mn) and Average Price (USD/Dose) (2018-2023)
Table 97. ANGANY Genetics Key News & Latest Developments
Table 98. CPL Biologicals Company Summary
Table 99. CPL Biologicals Virus Like Particles Product Offerings
Table 100. CPL Biologicals Virus Like Particles Sales (K Dose), Revenue (US$, Mn) and Average Price (USD/Dose) (2018-2023)
Table 101. CPL Biologicals Key News & Latest Developments
Table 102. Xiamen Innovax Biotech Company Summary
Table 103. Xiamen Innovax Biotech Virus Like Particles Product Offerings
Table 104. Xiamen Innovax Biotech Virus Like Particles Sales (K Dose), Revenue (US$, Mn) and Average Price (USD/Dose) (2018-2023)
Table 105. Xiamen Innovax Biotech Key News & Latest Developments
Table 106. Virus Like Particles Production Capacity (K Dose) of Key Manufacturers in Global Market, 2021-2023 (K Dose)
Table 107. Global Virus Like Particles Capacity Market Share of Key Manufacturers, 2021-2023
Table 108. Global Virus Like Particles Production by Region, 2018-2023 (K Dose)
Table 109. Global Virus Like Particles Production by Region, 2024-2029 (K Dose)
Table 110. Virus Like Particles Market Opportunities & Trends in Global Market
Table 111. Virus Like Particles Market Drivers in Global Market
Table 112. Virus Like Particles Market Restraints in Global Market
Table 113. Virus Like Particles Raw Materials
Table 114. Virus Like Particles Raw Materials Suppliers in Global Market
Table 115. Typical Virus Like Particles Downstream
Table 116. Virus Like Particles Downstream Clients in Global Market
Table 117. Virus Like Particles Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Virus Like Particles Segment by Type in 2022
Figure 2. Virus Like Particles Segment by Application in 2022
Figure 3. Global Virus Like Particles Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Virus Like Particles Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Virus Like Particles Revenue, 2018-2029 (US$, Mn)
Figure 7. Virus Like Particles Sales in Global Market: 2018-2029 (K Dose)
Figure 8. The Top 3 and 5 Players Market Share by Virus Like Particles Revenue in 2022
Figure 9. By Type - Global Virus Like Particles Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Virus Like Particles Revenue Market Share, 2018-2029
Figure 11. By Type - Global Virus Like Particles Sales Market Share, 2018-2029
Figure 12. By Type - Global Virus Like Particles Price (USD/Dose), 2018-2029
Figure 13. By Application - Global Virus Like Particles Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Virus Like Particles Revenue Market Share, 2018-2029
Figure 15. By Application - Global Virus Like Particles Sales Market Share, 2018-2029
Figure 16. By Application - Global Virus Like Particles Price (USD/Dose), 2018-2029
Figure 17. By Region - Global Virus Like Particles Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Virus Like Particles Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Virus Like Particles Revenue Market Share, 2018-2029
Figure 20. By Region - Global Virus Like Particles Sales Market Share, 2018-2029
Figure 21. By Country - North America Virus Like Particles Revenue Market Share, 2018-2029
Figure 22. By Country - North America Virus Like Particles Sales Market Share, 2018-2029
Figure 23. US Virus Like Particles Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Virus Like Particles Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Virus Like Particles Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Virus Like Particles Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Virus Like Particles Sales Market Share, 2018-2029
Figure 28. Germany Virus Like Particles Revenue, (US$, Mn), 2018-2029
Figure 29. France Virus Like Particles Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Virus Like Particles Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Virus Like Particles Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Virus Like Particles Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Virus Like Particles Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Virus Like Particles Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Virus Like Particles Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Virus Like Particles Sales Market Share, 2018-2029
Figure 37. China Virus Like Particles Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Virus Like Particles Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Virus Like Particles Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Virus Like Particles Revenue, (US$, Mn), 2018-2029
Figure 41. India Virus Like Particles Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Virus Like Particles Revenue Market Share, 2018-2029
Figure 43. By Country - South America Virus Like Particles Sales Market Share, 2018-2029
Figure 44. Brazil Virus Like Particles Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Virus Like Particles Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Virus Like Particles Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Virus Like Particles Sales Market Share, 2018-2029
Figure 48. Turkey Virus Like Particles Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Virus Like Particles Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Virus Like Particles Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Virus Like Particles Revenue, (US$, Mn), 2018-2029
Figure 52. Global Virus Like Particles Production Capacity (K Dose), 2018-2029
Figure 53. The Percentage of Production Virus Like Particles by Region, 2022 VS 2029
Figure 54. Virus Like Particles Industry Value Chain
Figure 55. Marketing Channels

※参考情報

ウイルス様粒子（Virus Like Particles, VLP）は、ウイルスの部分的な構造を模倣した微小な粒子であり、ウイルスそのものではないため、感染性を持たない特徴があります。これらの粒子は、ウイルスの表面タンパク質のみを構成要素として持ち、ウイルスゲノムやその他の複製機構が欠如しています。そのため、ウイルス様粒子は主にワクチン開発において重要な役割を果たしています。

ウイルス様粒子の定義としては、ウイルスの特定の構成部分（通常はカプシドタンパク質）が自己集合して形成される粒子を指します。これらの粒子は、ウイルスの抗原性を保持しつつ、感染能力を持たないため、安全に使用できる特徴があります。また、ウイルス様粒子は、いくつかの異なるウイルス由来で合成されることが可能であり、これにより異なる疾病に対するワクチンの開発が促進されています。

ウイルス様粒子の特徴としては、まず第一に、自己集合能力が挙げられます。ウイルスカプシドのタンパク質が適切な条件下で自己組織化し、安定した球状や多面体の構造を形成します。これにより、ウイルスによって引き起こされる免疫応答を模倣することができます。第二に、VLPは一般に無毒性であり、感染性のウイルスよりも安全性が高いことが挙げられます。これは、ウイルスゲノムを持たないため、自分自身を複製する能力がないためです。

ウイルス様粒子の種類としては、主に以下のようなものが挙げられます。まず、ヒトパピローマウイルス（HPV）由来のVLPは、子宮頸がん予防ワクチンに使用されています。次に、肝炎ウイルス（HBV）由来のVLPは、肝炎の予防に用いられます。また、インフルエンザウイルスやノロウイルスに基づいたVLPも、ワクチン開発において重要な役割を果たしています。さらに、最近の研究では、コロナウイルスに関連するVLPも注目を浴びており、COVID-19ワクチンの開発に利用される可能性があります。

用途としては、ウイルス様粒子は主にワクチン開発に用いられています。VLPを基にしたワクチンは、免疫系を刺激し、抗体を生成する能力が高いとされています。これにより、特定のウイルスに対する長期間の免疫を獲得することが可能になります。また、VLPを利用したワクチンは、アジュバントの使用を必要としない場合が多く、免疫応答を効果的に引き出すことができます。

さらに、ウイルス様粒子は、医薬品のドラッグデリバリーシステムとしての可能性も研究されています。VLPの内部に薬物を封入し、特定の細胞に標的化して放出することで、治療効果を高める手法が模索されています。このような利用法により、従来の治療法では困難だった薬物の効率的な投与が実現する可能性があります。

関連技術としては、遺伝子組換え技術や細胞工学が挙げられます。VLPの製造には、遺伝子工学を用いて特定のウイルスの遺伝子を大腸菌や酵母、昆虫細胞などに導入し、これによりウイルス様粒子を産生する技術が重要です。この工程では、ターゲットとなるウイルスの表面タンパク質が正しい形で発現されることが必要です。また、細胞工学を利用することで、VLPの生産を効率化したり、より複雑な構造を持つVLPの開発が可能になります。

さらに、バイオインフォマティクス技術も重要です。これにより、ウイルスの構造や抗原性の解析が行われ、新しく効果的なVLPの設計が可能となります。高解像度の構造解析技術（例：X線結晶解析、クライオ電子顕微鏡など）を用いることで、ウイルス様粒子の詳細な構造を理解し、それを基にしたデザインが進化しています。

総じて、ウイルス様粒子は様々な魅力的な特性を持ち、安全に使用できるワクチンの開発に貢献しています。今後もこの分野の研究は進み、より効果的で安全な医療製品の開発が期待されます。ウイルス様粒子の研究は、伝染病に対する新しい治療法や予防策を見出すための可能性を秘めており、未来の医療において重要な役割を果たすことでしょう。

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ ウイルス様粒子の世界市場見通し2023年-2029年(Virus Like Particles Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

ウイルス様粒子の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp